Reuters logo
10 months ago
BRIEF-Study confirms best-in-class status of Biocartis' Idylla kras mutation detection technology
October 11, 2016 / 5:11 AM / 10 months ago

BRIEF-Study confirms best-in-class status of Biocartis' Idylla kras mutation detection technology

Oct 11 (Reuters) - Biocartis Group NV :

* Astrazeneca comparative study confirms best-in-class status of Idylla kras mutation detection technology Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below